However, the development of therapeutics targeting the TGF-β pathway has been hindered mainly by its critical regulatory roles in normal physiology and due to its ability to function as both tumour promoter and inhibitor in a context-dependent manner [104]. This evidence concerns the gene TGFB1 and neoplasm.